Early Assessment of Minimal Residual Disease (MRD) by Qualitative PCR for NPM-ALK Identifies Patients At Very High Risk of Relapse in Anaplastic Large Cell Lymphoma

被引：0
|
作者：
Damm-Welk, Christine [1 ]
Mussolin, Lara [2 ]
Pillon, Marta [2 ]
Zimmermann, Martin [1 ]
Reiter, Alfred [1 ]
Woessmann, Wilhelm [1 ]
Rosolen, Angelo [2 ]
机构：
[1] Univ Giessen, Giessen, Germany
[2] Univ Padua, Padua, Italy
来源：
BLOOD | 2011年 / 118卷 / 21期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：680 / 680
页数：1
相关论文
共 50 条
  • [21] Quantitative Monitoring of NPM1 Mutation A Minimal Residual Disease Identifies Patients At High Risk for Relapse within the ELN Favorable Risk Group
    Hubmann, Max
    Subklewe, Marion
    Koehnke, Thomas
    Schneider, Stephanie
    Dufour, Annika
    Zellmeier, Evelyn
    Fiegl, Michael
    Hiddemann, Wolfgang
    Spiekermann, Karsten
    BLOOD, 2012, 120 (21)
  • [22] Prognostic Impact of Minimal Disseminated Disease By Digital PCR for Pediatric ALK-Positive Anaplastic Large Cell Lymphoma
    Fukano, Reiji
    Iijima-Yamashita, Yuka
    Iwafuchi, Hideto
    Nakazawa, Atsuko
    Saito, Akiko Moriya
    Takimoto, Tetsuya
    Sekimizu, Masahiro
    Suehiro, Yutaka
    Hasegawa, Shunji
    Mori, Tetsuya
    Horibe, Keizo
    BLOOD, 2022, 140 : 3506 - 3507
  • [23] Targeted siRNA inhibition of NPM-ALK in anaplastic large cell lymphoma causes disease specific growth inhibition which augments chemotherapeutic agents.
    Hsu, FY
    Anderson, WF
    Johnston, PB
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 841S - 841S
  • [24] Minimal residual disease in patients with anaplastic large cell lymphoma correlates with histological subtype and outcome
    Damm-Welk, C.
    Mussolin, L.
    Zimmermann, M.
    Pillon, M.
    Klapper, W.
    d'Amore, E.
    Reiter, A.
    Woessmann, W.
    Rosolen, A.
    BRITISH JOURNAL OF HAEMATOLOGY, 2012, 159 : 28 - 28
  • [25] Quantification of Minimal Disease by Digital PCR in ALK-Positive Anaplastic Large Cell Lymphoma: A Step towards Risk Stratification in International Trials?
    Damm-Welk, Christine
    Lovisa, Federica
    Contarini, Giorgia
    Luedersen, Jette
    Carraro, Elisa
    Knorr, Fabian
    Foerster, Jan
    Zimmermann, Martin
    Sala, Alessandra
    Vinti, Luciana
    Tondo, Annalisa
    Pillon, Marta
    Woessmann, Wilhelm
    Mussolin, Lara
    CANCERS, 2022, 14 (07)
  • [26] Post-CAR-T Minimal Residual Disease (MRD) Monitoring in Mantle Cell Lymphoma Enables Early Relapse Detection
    Ananth, Snegha
    Su, Yi-Jiun
    Hamilton, Mark P.
    Agarwal, Neha
    Weng, Wen-Kai
    Dahiya, Saurabh
    Bharadwaj, Sushma
    Mallampet, Jayasindhu
    Smith, Melody
    Kong, Katherine Ann
    Twoy, Abigail
    Miklos, David B.
    Frank, Matthew J.
    BLOOD, 2023, 142
  • [27] Nuclear NPM-ALK Protects Myc from Proteasomal Degradation and Contributes to Its High Expression in Cancer Stem-Like Cells in ALK-Positive Anaplastic Large Cell Lymphoma
    Shang, Chuquan
    Lai, Justine
    Haque, Moinul
    Chen, Will
    Wang, Peng
    Lai, Raymond
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2023, 24 (18)
  • [28] Nuclear NPM-ALK Protects Myc from Proteosomal Degradation and Contributes to High Protein Expression in Cancer Stem-like Cells in ALK-Positive Anaplastic Large Cell Lymphoma
    Shang, Chuquan
    Chen, Will
    Lai, Justine
    Haque, Moinul
    Wang, Peng
    Lai, Raymond
    BLOOD, 2022, 140 : 6452 - 6452
  • [29] High-sensitivity next-generation sequencing MRD assessment in ALL identifies patients at very low risk of relapse
    Short, Nicholas J.
    Kantarjian, Hagop
    Ravandi, Farhad
    Konopleva, Marina
    Jain, Nitin
    Kanagal-Shamanna, Rashmi
    Patel, Keyur P.
    Macaron, Walid
    Kadia, Tapan M.
    Wang, Sa
    Jorgensen, Jeffrey L.
    Khoury, Joseph D.
    Yilmaz, Musa
    Kebriaei, Partow
    Takahashi, Koichi
    Garcia-Manero, Guillermo
    Daver, Naval
    Post, Sean M.
    Huang, Xuelin
    Kornblau, Steven M.
    Pelletier, Sara
    Flores, Wilmer
    Matthews, Jairo
    Garris, Rebecca
    Jabbour, Elias
    BLOOD ADVANCES, 2022, 6 (13) : 4006 - 4014
  • [30] Characterization of minimal residual disease (MRD) post-radiotherapy (RT) in nasopharyngeal carcinoma (NPC) patients identifies a favorable subgroup with low risk of relapse
    Neo, J.
    Ong, E.
    Sim, A.
    Miao, J. J.
    Wee, J. T. S.
    Fong, K. W.
    Soong, Y. L.
    Sin, S. Y.
    Tan, D. S. W.
    Lim, D. W-T.
    Ang, M-K.
    Chua, M. L. K.
    ANNALS OF ONCOLOGY, 2022, 33 : S1523 - S1523
12345